FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
1. FDA approved self-injection for Argenx's Vyvgart Hytrulo in gMG and CIDP. 2. Self-injection allows 20-to-30-second administration, improving patient convenience. 3. Analysts expect significant growth in Vyvgart's market presence post-approval. 4. Self-administration may increase dosing frequency for better symptom management. 5. Argenx maintains first-to-market advantage amid competition in CIDP and MG.